Rezolute, Inc. (RZLT) Stock

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, dedicated to advancing therapies for metabolic diseases associated with chronic glucose imbalance. At the forefront of its development efforts is RZ358, a human monoclonal antibody currently undergoing Phase 2b clinical trials. This innovative therapy targets congenital hyperinsulinism, a rare genetic disorder primarily affecting pediatric patients, aiming to address the underlying metabolic dysregulation.

In addition to RZ358, Rezolute is actively progressing RZ402, an oral plasma kallikrein inhibitor, through Phase 1 clinical trials. This candidate is designed for the chronic treatment of diabetic macular edema, a complication of diabetes that affects the retina. By leveraging its expertise in biopharmaceutical research, Rezolute aims to develop therapeutic solutions that improve patient outcomes and quality of life in challenging metabolic conditions.

Originally founded as AntriaBio, Inc. and subsequently rebranded in December 2017, Rezolute, Inc. has established itself as a leader in addressing unmet medical needs through innovative drug development. The company collaborates with healthcare professionals and researchers to advance its pipeline, reflecting its commitment to transforming treatment options for patients worldwide.